Neuropathy Impact on Outcomes and Efficacy in HF Patients with Type 2 Diabetes: Insights from DAPA-HF and DELIVER Trials
New research found that Dapagliflozin reduces the relative and absolute risk of death and heart failure-related hospitalization due to diabetic neuropathy in individuals with Heart failure and Type 2 Diabetes. The trial results were published in the journal JACC: Heart Failure.
Diabetic neuropathy is one of the common complications of diabetes seen more in long-standing and poorly controlled diseases. Individuals with diabetic neuropathy can have worsened outcomes like a higher incidence of cardiovascular disease, including heart failure (HF) than those without. However, the relationship between neuropathy and clinical outcomes in patients with both diabetes and heart failure is not clearly understood. Additionally, it remains unclear whether neuropathy could affect the efficacy of heart failure treatments. To understand this better, researchers from Europe and America studied the effects on Diabetics.
Researchers conducted a post hoc analysis of two major heart failure trials: the DAPA-HF and DELIVER studies involving over 5,000 patients with HF and type 2 diabetes (T2D). Both trials were randomized, double-blind, and placebo-controlled, evaluating the effectiveness and safety of dapagliflozin, a medication used to treat heart failure, at a dose of 10 mg once daily. The key difference between the trials was the criteria for left ventricular ejection fraction (LVEF), with DAPA-HF enrolling patients with LVEF ≤40% and DELIVER enrolling those with LVEF >40%. Individuals with a previous history of type 2 diabetes or new-onset T2D were included in the analysis. Assessing a combination of worsening heart failure or cardiovascular death was the primary outcome. The study utilized various statistical models to determine time-to-event data and total events. Additionally, changes in patients’ quality of life were measured using the Kansas City Cardiomyopathy Questionnaire (KCCQ) scores, and the results were analyzed.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.